Report Overview

The South Korea dipeptide peptidase 4 (DPP-4) inhibitors market size stood at around USD 415.5 million in 2019 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx % during the forecast period.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral diabetes drugs. Also known as gliptins, they are usually prescribed for people with type 2 diabetes who have not responded well to drugs such asmetformin and sulphonylureas. DPP-4 inhibitors may help withweight lossas well as decreasing blood glucose levels.

They work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed and reduce the production ofglucagonby the liver when it is not needed. They also slow down digestion and decrease appetite.



Market Drivers

Increase in incidence of diabetes and its related complications such as cardiovascular disease, nephropathy, retinopathy, and neuropathy and rise in geriatric population fuel the market growth. DPP- 4 inhibitors also help in weight loss as they slow down the digestion and reduce appetite, so rise in the cases of obesity also propel the market drive. Furthermore, increasein clinical trials, research and development on the DPP-4 drugs is impacting the market positively. However, side effects such as urinary tract infection and respiratory tract infection restraints the market growth.